Researchers at Monash University have discovered that low-dose aspirin could reduce dementia risk by 70% in older adults with a specific genetic profile, though this benefit comes with increased bleeding risks.
- 70% lower dementia risk seen in people with specific platelet-related genes.
- Aspirin users faced a nearly doubled risk of major bleeding within this group.
- Genetics may guide future personalized dementia prevention strategies.
What happened
A team from Monash University analyzed genetic and health data from over 13,500 elderly participants in the ASPREE Trial to explore aspirin's effect on dementia risk. They examined genetic markers related to platelet counts, as platelets play a role in blood clotting and have been linked to dementia mechanisms.
The key finding was that individuals in the top 20% for platelet count genetic scores had a substantially lower risk of developing dementia if they took low-dose aspirin compared to those given a placebo. Specifically, only 1% of aspirin users in this group developed dementia, versus 3.3% of placebo recipients.
Why it feels good
This research opens an exciting possibility for more targeted dementia prevention tailored to a person's genetics. Unlike prior studies that showed no overall benefit of aspirin in lowering dementia risk, this work reveals that genetics could explain why some individuals might uniquely benefit.
Given the growing global challenge of dementia, with rising case numbers expected in many countries, such personalized approaches could lead to better outcomes and more effective use of existing medications. It also introduces platelet biology as a novel pathway worth exploring further in dementia research.
What to enjoy or watch next
While the findings are promising, the study also found that aspirin users in this genetic group faced an increased risk of major bleeding, nearly doubling compared to placebo. This highlights the need for cautious evaluation and balancing potential benefits with safety.
The next steps include validating these results in other populations and conducting clinical trials focused specifically on individuals with this genetic profile. As research progresses, keep an eye on advances in genetic testing and personalized medicine that might one day help decide who could safely benefit from aspirin or other preventive treatments for dementia.